|Bid||519.49 x 800|
|Ask||569.29 x 1000|
|Day's range||514.59 - 561.07|
|52-week range||318.45 - 659.45|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||99.81|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||522.55|
SAN DIEGO, November 29, 2021--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:
Case in point: shares of medical devices specialist DexCom (NASDAQ: DXCM) have soared by 86% in the trailing twelve-month period. There are excellent reasons to think DexCom could significantly outperform the market in the next decade. DexCom's goal is to improve the lives of diabetes patients.
Look out for companies that can latch on to strong long-term trends to add to when the market undergoes a correction.